United Therapeutics at Bernstein forum: growth bets widen

During the Bernstein Healthcare Leaders and Disruptors forum on September 23, 2026, United Therapeutics discussed its growth strategy centered around pulmonary fibrosis, pulmonary hypertension, and organ manufacturing. The company's CEO, Dr. Martine Rothblatt, emphasized the company's disruption within the industry rather than traditional leadership, citing its current market capitalization of about $20 billion.

United Therapeutics has 14 significant products in development or commercialization, along with several launched products. The company's structure, with approximately 1,700 employees, generates roughly $2 million in revenue per employee, a benchmark that only Gilead surpasses among comparable companies. Rothblatt highlighted that the company operates with fewer resources than employees might assume, employing a "Darwinian" approach to encourage strong performance.

The company has been aggressively buying back shares, investing in future manufacturing capacity, and using AI and digital modeling through CLIMB to guide drug development and minimize risk. Management also noted the FDA's acceptance of the NDA for nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), with a PDUFA date in early 2025.

Additionally, the once-daily Ralpi molecule, a new pill for IPF, PPF, and ILD, is expected to launch by 2030.